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Abstract 
Objective: To evaluate the anti-Candida effect of eugenol and its antimicrobial 
interaction with nystatin. Material and Methods: The antimicrobial potential was 
assessed by microdilution technique (M27A3 reference method), by determining the 
minimum inhibitory concentration (MIC) and the minimum fungicidal concentration 
(MFC) against C. albicans (ATCC 90028). The possible action of eugenol on the fungal 
cell wall was evaluated with the assistance of the osmotic protector sorbitol (0.8 M). The 
antimicrobial interaction with nystatin was assessed through the checkerboard method. 
All tests were performed in triplicate. Results: All groups showed reductions in PI and 
GBI values and improvements in oral health knowledge, but IG1 and IG2 showed 
statistically significant differences in these variables compared to CG. Conclusion: The 
eugenol has antifungal activity against C. albicans and its mechanism of action is 
probably not related to damage to the fungal cell wall. Association between eugenol and 
nystatin was not found to be an advantageous possibility for growth inhibition of C. 
albican. 
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Introduction 
Candidal species are opportunistic microorganisms involved in the most prevalent fungal 
infection in humans, known as candidiasis [1,2]. Among the various Candida species, C. albicans is 
considered the most frequent and pathogenic strain, being able to colonize and invade many mucosal 
surfaces [1,3,4]. The virulence of C. albicans is linked to the ability of such microorganism in forming 
biofilms, performing morphogenesis to a filamentous form, invading soft tissues, and secreting 
phospholipases and proteinases [1,3]. 
Many strategies are known to fight candidal infections, including the use of antifungals with 
systemic or topic effect, showing a fungistatic or fungicidal action [5]. Antimycotic agents such as 
azoles, polyenes and antimetabolites agents (i.e. nystatin, amphotericin b, fluconazole, miconazole, 
itraconazole, and 5-Fluorocytosine) are recognized as the main choice-drugs for candidiasis 
treatment [5,6]. However, with regards to oral candidiasis, a local antimicrobial agent is preferred, 
in order to produce better efficacy due to higher drug penetration and retention; also avoiding 
systemic side effects [7]. 
Resistance to some of widely-used antifungals has been recently reported in the literature 
[8,9]. Considering this, new strategies for fungal infection control are necessary to improve the 
efficacy of such treatments [10]. Based on that, recent studies had given evidence to antimicrobial 
compounds extracted from plants, in a form of essential oils, crude extracts, and molecules, such as 
flavonoids and terpenes [8,11,12]. Recent studies have also focused on the association between 
natural products and conventional pharmacological agents in order to achieve better efficacy of 
treatments [12-15]. 
Regarding the clinical use of natural compounds extracted from plants, eugenol is recognized 
as a therapeutic agent widely handled in Dentistry, also presenting antimicrobial, anti-septic, 
analgesic, and anti-inflammatory properties [16]. Given the biological properties of such compound, 
it is hypothesized that association with a synthetic antifungal would improve efficacy of both. 
Therefore, the aim of this study is to evaluate the anti-Candida effect of eugenol and its antimicrobial 
interaction with nystatin. 
 
Material and Methods 
Experimental Design  
An in vitro study was performed to determine the minimum inhibitory concentration (MIC) 
and minimum fungicidal concentration (MFC) of eugenol and nystatin against C. albicans. In 
addition, the influence of eugenol on the integrity of cell wall was determined by the sorbitol test. 
Finally, a checkerboard method was used to determine the interaction between eugenol and nystatin.   
 
Inoculum standardization 
C. albicans (ATCC 90028) reference strain was used in all experiments. Lyophilized stocks 
were acquired from the National Institute of Quality in Health (INCQS, Fundação Oswaldo Cruz, 
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Rio de Janeiro, RJ, Brazil). Reactivation procedures involved suspension of microorganisms in 
Sabouraud Dextrose Broth (SDB, HiMedia Laboratories, Mumbai, India) and cultivation in 
Sabouraud Dextrose Agar plates (SDA, HiMedia Laboratories, Mumbai, India). Inoculum was 
standardized by suspension of three to five C. albicans colonies in 5 mL of saline. Resulted suspension 
was then compared to the point 0.5 from the McFarland scale, also showing an absorbance of 0.1 at 
600 nm, which corresponds to approximately 1 × 106 colony forming units per milliliter (CFU/mL). 
For all assays, the standardized suspension of C. albicans was diluted 1000× Sabouraud Dextrose 
Broth (HiMedia Laboratories, Mumbai, India), in order to generate a working suspension with 1 × 
103 CFU/mL, following the Clinical and Laboratory Standards Institute (CLSI) recommendation 
[17]. 
 
Testing Substances and Preparation  
Eugenol was obtained in its commercial formula used in Dentistry (Eugenol USP, 99.9% 
purity, Maquira Dental Products, Maringa, PR, Brazil). Eugenol working solutions were prepared at 
10,000 μg/mL by diluting 100 μL of eugenol in 9.9 mL of SDB with 2% emulsifier agent (v/v) 
(Tween 80, Sigma-Aldrich, St. Louis, MO, USA). Nystatin (Sigma-Aldrich, St. Louis, MO, USA) 
working solutions were prepared at 800 μg/mL by dilution in SDB. 
 
Minimum Inhibitory Concentration (MIC) and Minimum Fungicidal Concentration (MFC) 
MIC was determined by the micro-dilution method, following the M27A3 guideline of the 
CLSI [17]. Initially, 100 μL of SDB culture medium was distributed along all wells from a 96-well 
microtiter plate. After that, 100 μL of eugenol (10,000 μg/mL) and nystatin (800 μg/mL) working 
solutions were added to the first line of the microtiter plate, followed by a two-fold serial dilution 
along all subsequent wells. Concentrations of eugenol ranged from 2,500 μg/mL to 19.5 μg/mL; 
whilst nystatin concentrations ranged from 200 μg/mL to 1.56 μg/mL. Finally, 100 μl of C. albicans 
(1×103 CFU/mL) inoculum was added to each test well [17]. Positive and negative controls 
consisted of wells without antimicrobials and without microorganisms, respectively. Plates were then 
incubated at 37ºC, for 24 h. 
 The MIC was defined as the lowest concentration that inhibited at least 80% of microbial 
growth, initially identified by visual method. Microbial growth was perceptible by culture medium 
turbidity and/or by cellular precipitation. In order to confirm the presence of microbial viability in 
non-inhibitory concentrations, an aliquot of 50 μL of 2,3,5-triphenyl tetrazolium chloride (TTC, 
Sigma-Aldrich, St. Louis, MO, USA) was added to each test well. After incubation (37ºC, 24 h), 
viable microorganisms resulted in a color change for non-inhibitory wells [18]. 
After that, MFC was assessed by sub-cultivation of 20 μL aliquots from tested wells on SDA 
plates. MFC was defined as the lowest concentration that yielded no cultured microorganisms. 
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Eugenol Effect on Fungal Cell Wall 
The possible mechanism by which eugenol would affect C. albicans viability was assessed by 
sorbitol test [19]. In this evaluation, an osmotic protector (Sorbitol 0.8 M) is used during 
antimicrobial assays in order to check differences on MIC values, in the presence or absence of 
sorbitol. Therefore, MIC evaluation was replicated using culture medium supplemented with 
Sorbitol 0.8 M. Briefly, if the MIC of tested substance does not change, it is said that the mechanism 
of action is not involved with osmotic pressure and cell wall degradation; however, if the MIC value 
increases in the presence of sorbitol, it is said that tested substance interferes with osmotic pressure 
and cell wall degradation. Caspofungin was used as a positive control in this assay at an initial 
concentration of 5 µg/mL (caspofungin diacetate – Sigma-Aldrich, São Paulo, SP, Brazil). 
 
Antimicrobial Interactions: Checkerboard Method 
The checkerboard method was used to evaluate the interaction between eugenol and nystatin 
in producing an antimicrobial effect. By means of checkerboard, a fractionated inhibitory 
concentration index (FICI) was determined and the interaction between substances was interpreted 
as synergistic, additive, indifferent or antagonist. 
Briefly, 100 μL of culture medium containing 1 × 103 CFU/mL of C. albicans was added in 
each well of a 96-well microtiter plate. Each of the tested solutions was evaluated at seven different 
concentrations, according to previously determined MIC. Therefore, working solutions at 
concentrations MIC÷8, MIC÷4, MIC÷2, MIC, MIC×2, MIC×4 and MIC×8 were previously 
prepared. After that, 50 μL of eugenol solutions were added horizontally, whilst 50 μL of nystatin 
solutions were added vertically in seven subsequent wells. According to that, each working 
concentration of eugenol was combined with each concentration of nystatin, and the opposite is also 
true. After incubation at 37ºC, for 24 h, the inhibitory concentrations of each substance were 
assessed. The absence of cellular growth and viability was determined as previously described 
[20,21]. 
Within each substance, the lowest inhibitory concentration was considered as minimum 
inhibitory concentration in combination (MICC). Interpretation of data was based on FICI 
calculation, which considered both the MIC and MICC of each substance, using the following 
formula:  𝐹𝐼𝐶𝐼 = 𝑀𝐼𝐶𝐶𝑀𝐼𝐶 𝑒𝑢𝑔𝑒𝑛𝑜𝑙 +    𝑀𝐼𝐶𝐶𝑀𝐼𝐶 𝑛𝑦𝑠𝑡𝑎𝑡𝑖𝑛  
 
Resulting values were interpreted as the following: synergistic (FICI < 0.5), additive (0.5 < 
FICI < 1.0), indifferent (1.0 < FICI < 4.0), or antagonist (FICI > 4.0) [21,22]. 
 
Results 
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Both eugenol and nystatin, at evaluated concentrations, inhibited the cellular growth of C. 
albicans (ATCC 90028) in the present study. MIC and MFC values of both substances under the 
conditions studied are shown in Table 1. The presence of an osmotic protector did not interfere with 
the antimicrobial effect of eugenol, as also shown in Table 1. 
 
Table 1. MIC and MFC, in µg/mL, of eugenol and nystatin against C. albicans (ATCC 900280). MIC 
and MFC were evaluated in the presence (+) or absence (−) of an osmotic protector (sorbitol). 
Substance MIC MFC 
+ sorbitol − sorbitol + sorbitol − sorbitol 
Eugenol 625 625 625 625 
Nystatin 25 * 25 * 
Caspofungin < 0.0003 > 0.0045 * * 
* Not evaluated. 
 
Antimicrobial interaction of eugenol and nystatin was assessed by checkerboard method, by 
which a MICC was determined for each substance. The lowest inhibitory concentration of eugenol 
persisted at 625 µg/mL (MICCeugenol), whilst lowest inhibitory concentration of nystatin in the 
presence of eugenol was detected at 3.125 µg/mL (MICCnystatin), as shown in Table 2. Antimicrobial 
interactions between eugenol and nystatin were considered “indifferent”. 
 
Table 2. MICC, in µg/mL, of eugenol and nystatin against C. albicans (ATCC 900280), assessed by the 
checkerboard method. Antimicrobial interaction was determined by FICI calculation and 
interpretation. 
Substance 
MICC 
MICC 
MIC 
FICI Interaction’s Interpretation 
Eugenol 625 1.0 
1.125 Indifferent 
Nystatin 3.125 0.125 
 
Discussion 
Natural products consist a very rich source of new bioactive compounds, which deserve 
investigation to find out or confirm its popular use [10, 23,24]. The eugenol has been widely used in 
Dentistry for many years, due to its antimicrobial, analgesic, anti-oxidant, and anti-inflammatory 
properties [25]. Eugenol is more frequently used in the composition of some dental materials; 
usually in association with zinc oxide, in order to improve the biological effects. Considering that the 
microorganism C. albicans can habit many sites of the human body, causing significant health 
problems, authors were interested in detecting the antimicrobial effect of eugenol and its association 
with nystatin. In the present study, authors demonstrated that eugenol has a significant inhibitory 
effect on C. albicans. In addition, it is shown that association with nystatin is not antagonistic, 
although it is not synergistic either. 
It is well known that Candida species can colonize both hard and soft tissues [4]. Therefore, 
with regards to oral environment, Candida can participate not only in the pathogenesis of oral 
candidiasis [1], but also in endodontic, periodontal and peri-implant infections [26]. Clinically, it is 
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suggested that eugenol could be used as an adjuvant substance to the control of C. albicans infection, 
especially in endodontic infection, as a component of zinc oxide pastes [27]. 
Although several studies have investigated the antifungal effect of eugenol [14,28-30], the 
mechanisms by which eugenol induces C. albicans cell death are not completely understood yet. In 
this study, the osmotic protective effect of sorbitol was not present, since there was no variation in 
the values of MIC, similarly to a previous investigation [30]. Based on that, it can be stated that the 
mechanism of action of eugenol against C. albicans is probably not related to the degradation of 
fungal cell wall. Possibly, other mechanisms such as inactivation of ergosterol synthesis and 
production of free radicals, can be responsible for the antimicrobial effect of eugenol [28,29]. 
In vitro studies have shown satisfactory results regarding the association between natural 
products and conventional antimicrobials directed for antifungal therapy [13-15]. In a study 
conducted in India [15], the authors showed that the addition of eugenol and carvacrol to 
fluconazole have significantly reduced the concentration of the latter, in inhibition of biofilm growth 
by C. albicans. According to the aforementioned study, these terpenes cause instability in the fungal 
membrane and intervention in specific signals, facilitating greater fluconazole influx to the 
intracellular environment and culminating in inhibition of biofilm formation [15]. 
In the present study, the antimicrobial interaction test resulted in “indifference”, regarding 
the association between eugenol and nystatin against C. albicans. This means eugenol does not 
constitute an advantageous possibility to nystatin in inhibiting fungal growth. Similarly, Indian 
researchers [14] evaluated the antifungal activity of the association between terpenes (thymol, 
eugenol, and menthol) and fluconazole through antimicrobial interaction test. The authors found 
better results by associating the drug with thymol; whilst eugenol showed higher fungicidal activity 
when used alone [14]. 
Overall, the absence of additive or synergistic interaction between nystatin and eugenol does 
not invalidate the development of further pharmacological and microbiological studies involving 
such substances. Considering an endodontic infection with the presence of C. albicans, eugenol and 
nystatin could be an additive substance for additional antimicrobial effect. In addition, eugenol 
combination with other conventional anti-fungal and antimicrobials should be considered in future 
investigations. 
 
Conclusion 
The results of present study support that eugenol has antimicrobial potential against C. 
albicans, being its mechanism of action not related with damage to the fungal cell wall. The 
association between eugenol and nystatin does not constitute a significant pharmacological 
advantage against C. albicans; although those substances did not influence each other. 
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